Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Slingshot has won Novo Nordisk and the Dry July Foundation as clients.The announcement:Independent creative media agency, ...

Novo Nordisk, the Danish pharmaceutical giant behind obesity drug, Wegovy, has engaged Slingshot to develop and manage its ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Riding on a surge in global demand for its patented obesity and diabetes medicines Ozempic, Wegovy and Rybelsus, ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...